Back to results
US 7,803,556 B2Granted
Plant PR-5 proteins as mammalian therapeutic agents
AssigneePurdue Research Foundation
InventorsRay A. Bressan, Meena L. Narasimhan
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneePurdue Research Foundation
InventorsRay A. Bressan, Meena L. Narasimhan
Estimating the term…
The Proteins of the PR-5 family having a lectin-like β barrel domain control apoptosis in yeast through receptor binding. Receptors that specifically bind to PR-5 proteins having a lectin-like β barrel domain have been found to be homologous to mammalian adiponectin receptors, and such PR-5 proteins can act as functional homologues of adiponectin and control adiponectin response in mammals. PR-5 proteins having a lectin-like β barrel domain, for example osmotin, can be used in the treatment of conditions in mammals which are the result of activation or inhibition of adiponectin receptor-mediated metaboloic pathways. PR-5 proteins having a lectin-like β barrel domain, nucleic acids encoding such proteins, and receptors that specifically bind such proteins, can also be used in screening and rational design of new therapeutic agents for use in mammals.
A method for identifying an agent that modifies the binding of a PR-5 protein having a lectin-like β barrel domain to an adiponectin receptor in mammalian cells, said method comprising:
A method for identifying an agent that modifies the binding of an osmotin protein and a PHO36 receptor, said method comprising:
Dependencies are inferred from the claim text.